Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Revolution Medicines announced that Steve Kelsey, President of R&D, will transition to Senior Advisor to the CEO on July 1, 2026, and retire from employment in January 2027, at which point he is expected to join the Board of Directors. The company is implementing a new R&D leadership structure effective July 1, with Chief Development Officer Alan Sandler and Chief Scientific Officer Jan Smith overseeing their respective departments, while Xiaolin Wang assumes the new role of EVP of integrated portfolio strategy. Dr.
Key figures
- Retirement date
- January 4, 2027
- Transition date
- July 1, 2026
- Kelsey tenure start
- March 2017
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.